Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Study to Determine Long-term Safety of Mepolizumab in Asthmatic Subjects

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: April 25, 2013
Last updated: November 13, 2014
Last verified: November 2014

This is a multi-centre, open-label long-term safety study of 100 milligram (mg) mepolizumab administered subcutaneously (SC) every 4 weeks for 12 months in addition to standard of care in subjects who have severe, refractory asthma and a history of eosinophilic inflammation. Subjects who completed either MEA115588 or MEA115575 will be offered the opportunity to consent for this study.

Condition Intervention Phase
Biological: Mepolizumab
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: MEA115661: A Multi-centre, Open-label, Long-term Safety Study of Mepolizumab in Asthmatic Subjects Who Participated in the MEA115588 or MEA115575 Trials

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Number of subjects with Adverse Events (AEs) [ Time Frame: Up to 64 weeks ] [ Designated as safety issue: No ]
    AEs including non- serious and serious adverse events (SAEs). An AE is any untoward medical occurrence temporally associated with the use of the medicinal product, whether or not considered associated with the product. A serious AE is any medical occurrence that results in death, is life-threatening, require hospitalization or prolongation of an existing hospital stay, results in disability or incapacity, congenital anomaly, or is an "Hy's Law event (type of drug-induced liver injury)

  • Frequency of adverse events both systemic (i.e., allergic and non-allergic) and local site reactions [ Time Frame: Up to 64 weeks ] [ Designated as safety issue: No ]
    Safety monitoring including allergic, non-allergic and local site reactions are reported after the first 3 doses.

  • Number of subject withdrawals due to AEs [ Time Frame: Up to 64 weeks ] [ Designated as safety issue: No ]
    Number of subject withdrawals due to adverse events

  • Number of subjects hospitalized due to AEs including asthma exacerbations [ Time Frame: Up to 64 weeks ] [ Designated as safety issue: No ]
    Exacerbations is defined as worsening of asthma which requires use of systemic corticosteroids and/or hospitalisation and/or emergency department visits

  • 12-Lead ECG measurements to assess safety [ Time Frame: Up to 64 weeks ] [ Designated as safety issue: No ]
    Electrocardiogram (ECG) measurements include QT and QTc interval, it will be made after the subject has rested in the supine position for 5 minutes. Mean change from baseline in the QTc(F) (QT interval corrected by Friderica's method) Mean change from baseline in QTc(B) (QT interval corrected by Bazett's method), Maximum change from baseline for QTc(F) and QTc(B) will be measured.

  • Vital signs measurements to assess safety [ Time Frame: Up to 64 weeks ] [ Designated as safety issue: No ]
    Vital signs including sitting pulse rate and blood pressure measurements

  • Clinical laboratory measurements to assess safety [ Time Frame: Up to 64 weeks ] [ Designated as safety issue: No ]
    Clinical laboratory tests as measured by abnormal parameters for hematology and clinical chemistry

Secondary Outcome Measures:
  • Frequency of positive anti-mepolizumab binding antibodies and neutralizing antibodies [ Time Frame: Up to 64 weeks ] [ Designated as safety issue: No ]
    Blood samples will be collected for the determination of anti-mepolizumab antibodies, just prior to administration of mepolizumab. Samples testing positive for anti-mepolizumab antibodies will be further tested for neutralising antibody

  • Annualized rate of exacerbations [ Time Frame: Up to 64 weeks ] [ Designated as safety issue: No ]
    Exacerbations are defined as worsening of asthma which requires use of systemic corticosteroids and/or hospitalisation and/or emergency department visits

  • Asthma Control Questionnaire score (ACQ) [ Time Frame: Up to 64 weeks ] [ Designated as safety issue: No ]
    The ACQ-5 is a five-item questionnaire. Five questions are scored on a six point scale. (0= no impairment/limitation, 6= total impairment/ limitation). Total score range from 0 to 30. Higher score indicates greater impairment

  • FEV1 measured by clinic spirometry [ Time Frame: Up to 52 weeks ] [ Designated as safety issue: No ]
    Forced Expiratory Volume in 1 second (FEV1) is the maximal amount of air that can be forcefully exhaled in one second

  • Number of subject withdrawals due to lack of efficacy [ Time Frame: Up to 64 weeks ] [ Designated as safety issue: No ]
    Number of subject withdrawals due to lack of efficacy are summarized

Estimated Enrollment: 660
Study Start Date: May 2013
Estimated Study Completion Date: April 2015
Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Mepolizumab Arm
Subjects will receive 100 mg of Mepolizumab (in polypropylene syringe) injected subcutaneously (SC) once every 4 weeks for 12 months
Biological: Mepolizumab
Mepolizumab (a fully humanised IgG antibody) 100 mg injected SC once every 4 weeks for 12 months. Mepolizumab will be provided as a lyophilised cake in sterile vials


Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category.
  • Informed Consent: Prior to commencing any study related activities, subjects must be able and willing to provide written informed consent.
  • MEA115588 or MEA115575 study completion: Completion of the double-blind investigational product treatment during MEA115588 or MEA115575.
  • Current Anti-Asthma Therapy: Asthma is currently being treated with a controller medication (i.e., inhaled corticosteroids [ICS] or other asthma controlled medication) and the subject has been on a controller medication for the past 12 weeks. Subjects will be expected to continue controller therapy for the duration of the study.
  • Male or eligible female subjects:
  • To be eligible for entry into the study, females of childbearing potential must commit to consistent and correct use of an acceptable method of birth control for the duration of the trial and for 4 months after the last study drug administration.
  • A serum pregnancy test is required of all females at the initial Baseline Visit (Visit 1). In addition, a urine pregnancy test will be performed for all females prior to enrollment, during each scheduled study visit prior to the injection of investigational product, and during the Follow-up Visit.

Exclusion Criteria:

  • Hypersensitivity: Hypersensitivity reaction related to study medication during the MEA115588 or MEA115575 that led to patient withdrawal. Subjects who experienced a localized injection site reaction do not need to be excluded.
  • Health Status: Clinically significant change in health status during MEA115588 or MEA115575 which in the opinion of the investigator would make the subject unsuitable for participation in this long-term study.
  • Malignancy: A current malignancy or malignancy that developed during MEA115588 or MEA115575 (subjects that had localized carcinoma of the skin which was resected for cure will not be excluded). [Note for South Korea: Korean subjects with a diagnosis of malignancy within 5 years are excluded]
  • Prior SAE: A study related SAE in MEA115588 or MEA115575 that was assessed as possibly related to study medication by the investigator.
  • Pregnancy: Subjects who are pregnant or breastfeeding. Subjects should not be enrolled if they plan to become pregnant during the time of study participation.
  • ECG: Baseline ECG which has a clinically significant abnormality or which shows corrected QT interval with Fridericia (QTcF) >=450 millisecond (msec) or QTcF >=480 msec for subjects with Bundle Branch Block.
  • Smoking status: Current smokers
  • Liver Function: Liver function tests that meet any of the following during one of the last treatment visits in MEA115588 or MEA115575 : alanine transaminase (ALT) >=2 x upper limit of normal (ULN); aspartate transaminase (AST) >=2 x ULN; alkaline phosphatase >=2 x ULN; Bilirubin >1.5 x ULN (isolated bilirubin >1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin is <35%
  • Hepatitis Status: Positive Hepatitis B Surface Antigen (HBsAg) screen at Visit 1
  • ECG Over-read: Clinically significant abnormality identified during the central over-read during one of the last treatment visits in MEA115588 or MEA115575
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01842607

  Show 137 Study Locations
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline Identifier: NCT01842607     History of Changes
Other Study ID Numbers: 115661
Study First Received: April 25, 2013
Last Updated: November 13, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by GlaxoSmithKline:
extension study
Severe refractory asthma processed this record on November 20, 2014